PT  - JOURNAL ARTICLE
AU  - Ofra Amir
AU  - Yair Goldberg
AU  - Micha Mandel
AU  - Yinon M. Bar-On
AU  - Omri Bodenheimer
AU  - Laurence Freedman
AU  - Sharon Alroy-Preis
AU  - Nachman Ash
AU  - Amit Huppert
AU  - Ron Milo
TI  - Protection against omicron severe disease 0-7 months after BNT162b2 booster
AID  - 10.1101/2022.05.04.22274647
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.04.22274647
4099  - http://medrxiv.org/content/early/2022/05/05/2022.05.04.22274647.short
4100  - http://medrxiv.org/content/early/2022/05/05/2022.05.04.22274647.full
AB  - Following a rise in cases due to the delta variant and evidence of waning immunity after 2 doses of the BNT162b2 vaccine, Israel began administering a third BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the omicron variant compared to the delta variant and that this protection wanes quickly. In this study, we used data from Israel to estimate the protection of the 3rd dose against severe disease up to 7 months from receiving the booster dose. The analysis shows that protection conferred by the 3rd dose against omicron did not wane over a 7-month period and that a 4th dose further increased protection, with a severe disease rate approximately 3-fold lower than in the 3-dose cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Sheba Medical Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe individual-level data used in this study cannot be publicly shared even if anonymized due to privacy restrictions.